Iovance Biotherapeutics Inc (NASDAQ: IOVA) is 114.88% higher on its value in year-to-date trading and has touched a low of $3.21 and a high of $17.28 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The IOVA stock was last observed hovering at around $16.60 in the last trading session, with the day’s gains setting it 0.87%.
Currently trading at $17.47, the stock is 69.92% and 93.76% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 11.43 million and changing 5.24% at the moment leaves the stock 152.23% off its SMA200. IOVA registered 149.57% gain for a year compared to 6-month gain of 184.07%. The firm has a 50-day simple moving average (SMA 50) of $6.49k and a 200-day simple moving average (SMA200) of -$11.00.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The stock witnessed a 130.17% loss in the last 1 month and extending the period to 3 months gives it a 201.73%, and is 45.22% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 14.28% over the week and 9.86% over the month.
Iovance Biotherapeutics Inc (IOVA) has around 503 employees, a market worth around $4.87B and $0.71M in sales. Profit margin for the company is -61241.44%. Distance from 52-week low is 444.24% and 1.10% from its 52-week high. The company has generated returns on investments over the last 12 months (-58.27%).
Iovance Biotherapeutics Inc quarterly earnings per share for the current quarter are estimated at -$0.43 with sales reaching $1.39M over the same period.The EPS is expected to grow by 24.87% this year.
Iovance Biotherapeutics Inc (IOVA) Top Institutional Holders
333 institutions hold shares in Iovance Biotherapeutics Inc (IOVA), with institutional investors hold 85.28% of the company’s shares. The shares outstanding are 278.93M, and float is at 214.41M with Short Float at 19.57%. Institutions hold 84.83% of the Float.
The top institutional shareholder in the company is Vanguard Group Inc with over 20.4 million shares valued at $143.58 million. The investor’s holdings represent 8.23% of the IOVA Shares outstanding. As of Jun 29, 2023, the second largest holder is Blackrock Inc. with 17.0 million shares valued at $119.69 million to account for 6.86% of the shares outstanding. The other top investors are Perceptive Advisors Llc which holds 14.04 million shares representing 5.66% and valued at over $98.82 million, while State Street Corporation holds 5.48% of the shares totaling 13.57 million with a market value of $95.5 million.
Iovance Biotherapeutics Inc (IOVA) Insider Activity
The most recent transaction is an insider purchase by Rothbaum Wayne P.,the company’sDirector. SEC filings show that Rothbaum Wayne P. bought 5,000,000 shares of the company’s common stock on Feb 20 at a price of $9.15 per share for a total of $45.75 million. Following the purchase, the insider now owns 28.07 million shares.
Iovance Biotherapeutics Inc disclosed in a document filed with the SEC on Feb 20 that MCPEAK MERRILL A (Director) bought a total of 250,000 shares of the company’s common stock. The trade occurred on Feb 20 and was made at $9.15 per share for $2.29 million. Following the transaction, the insider now directly holds 0.32 million shares of the IOVA stock.
Still, SEC filings show that on Feb 20, Dukes Iain D. (Director) acquired 32,000 shares at an average price of $9.15 for $0.29 million. The insider now directly holds 54,000 shares of Iovance Biotherapeutics Inc (IOVA).
Iovance Biotherapeutics Inc (IOVA): Who are the competitors?
The company’s main competitors (and peers) include Pfizer Inc. (PFE) that is trading -33.72% down over the past 12 months. Merck & Co. Inc. (MRK) that is 21.45% higher over the same period.
